Drexel University Dornsife School of Public Health, and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Obstet Gynecol. 2022 Apr 1;139(4):537-544. doi: 10.1097/AOG.0000000000004709. Epub 2022 Mar 10.
To understand perspectives on and preferences for preexposure prophylaxis (PrEP) for pregnant individuals who are at risk for human immunodeficiency virus (HIV) infection.
In this qualitative study, we purposively sampled and conducted in-depth interviews with pregnant participants at risk of HIV infection (indicated by a recent sexually transmitted infection [STI]) from a U.S. urban obstetrics clinic. Interview questions focused on perceived HIV risk, knowledge and perceptions of PrEP, and preferences for different PrEP formulations. We coded data using deductive and inductive codes, created matrices to explore patterns in findings, and wrote memos to interpret emergent themes.
Twenty patients were enrolled. Median age of the participants was 24 years (interquartile range 19-26 years), 95.0% were African American, 65.0% were high school graduates, and 70.0% had unplanned pregnancies. Participants had low knowledge of PrEP and most saw themselves at low to no risk of HIV acquisition, despite their recent STI. Further, participants' low HIV risk perception and medication safety concerns reduced PrEP acceptability. Moreover, very few had discussed PrEP with their obstetrician-gynecologists (ob-gyns) during antenatal care, which further affected perceived acceptability. However, participants who did discuss PrEP with their ob-gyns had favorable perceptions of it. These participants indicated that they would choose a formulation based on individual preferences, which were largely shaped by perceived ease of use, acceptability, and prior experience with other medication regimens.
Obstetrician-gynecologists may play an important role in increasing pregnant individuals' knowledge of and access to PrEP during pregnancy among those who are at risk of HIV acquisition. To maximize uptake and adherence during this time, PrEP formulations should be tailored to individual preferences. Prevention of HIV during this critical life transition is important not only for the long-term health and well-being of pregnant individuals and their infants, but to the plan to end the HIV epidemic in the United States by 2030.
了解有感染人类免疫缺陷病毒(HIV)风险的孕妇对暴露前预防(PrEP)的看法和偏好。
在这项定性研究中,我们从美国一家城市妇产科诊所中,有针对性地选择了处于 HIV 感染风险(最近患有性传播感染 [STI])的孕妇进行深入访谈。访谈问题集中在感知的 HIV 风险、对 PrEP 的了解和看法以及对不同 PrEP 制剂的偏好。我们使用演绎和归纳代码对数据进行编码,创建矩阵以探索研究结果的模式,并撰写备忘录以解释出现的主题。
共纳入 20 名患者。参与者的中位年龄为 24 岁(四分位间距 19-26 岁),95.0%为非裔美国人,65.0%为高中毕业生,70.0%为意外怀孕。参与者对 PrEP 的了解程度较低,尽管他们最近患有 STI,但大多数人认为自己感染 HIV 的风险低或没有。此外,参与者对 HIV 风险的低感知和对药物安全性的担忧降低了 PrEP 的可接受性。此外,在产前保健期间,很少有参与者与妇产科医生(ob-gyn)讨论过 PrEP,这进一步影响了可接受性。然而,那些与 ob-gyn 讨论过 PrEP 的参与者对其有较好的看法。这些参与者表示,他们会根据个人偏好选择制剂,这些偏好主要受易用性、可接受性和之前对其他药物治疗方案的经验的影响。
妇产科医生在提高有 HIV 感染风险的孕妇对 PrEP 的认识和获取方面可能发挥重要作用。为了在这一时期最大限度地提高接受率和依从性,PrEP 制剂应根据个人偏好进行定制。在这一关键的生命过渡时期预防 HIV 不仅对孕妇及其婴儿的长期健康和福祉很重要,而且对 2030 年美国终结 HIV 疫情的计划也很重要。